NAD+ IV for Addiction Recovery: Does It Actually Work?

Wellness and detox clinics increasingly market intravenous NAD+ infusions as a way to ease withdrawal, reduce cravings, and "repair" the brain after substance use — targeting people seeking help for opioid, alcohol, and benzodiazepine dependence. The pitch is compelling, the price tag is high (multi-day "NAD+ detox protocols" often run $1,000–$5,000+), and the population being targeted is among the most vulnerable in medicine. The published evidence base tells a different story: as of July 2026, there are zero published randomized controlled trials of IV NAD+ infusion for any addiction, withdrawal, or craving-reduction indication. The strongest published data is a single uncontrolled, open-label pilot of 50 patients — authored partly by the inventor of the treatment being studied — with no placebo arm and self-reported Likert-scale outcomes. This evidence review covers what IV NAD+ clinics claim, what the mechanism rationale actually says, what the published evidence really shows, and why substituting an unproven infusion for evidence-based addiction care carries real risk. See also our NAD+ guide for a broader overview of NAD+ biology, and NAD+ IV cost and evidence for the general cost-versus-evidence verdict.

What IV NAD+ clinics claim it does for addiction

Clinics offering IV NAD+ for addiction recovery make a cluster of overlapping claims. The most common: that NAD+ infusions ease acute withdrawal symptoms from opioids, alcohol, and benzodiazepines by restoring depleted brain chemistry; that they reduce cravings by "resetting" dopamine and reward pathways; that they accelerate detoxification by improving cellular energy metabolism; and that they repair brain cells damaged by chronic substance use. Some clinics advertise multi-day inpatient-style "NAD+ detox protocols" lasting 4–10 days, with daily infusions, positioning the treatment as a gentler or more natural alternative to medication-assisted treatment.

The marketing often invokes real neuroscience concepts — dopamine deficiency, reward circuitry disruption, mitochondrial dysfunction — to lend biological authority to the claims. The disconnect is that having a plausible mechanism is not the same as demonstrating clinical efficacy in a controlled trial. The biological rationale for NAD+ in addiction exists and is worth understanding; the clinical evidence for IV NAD+ specifically does not^[3].

The proposed biological mechanism

The mechanistic case for NAD+ in addiction touches on two distinct pathways, and it is important to keep them conceptually separate.

First, the alcohol-specific pathway. Ethanol metabolism consumes NAD+ directly. Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) — the two primary enzymes that convert ethanol to acetaldehyde and then to acetate — each use NAD+ as a cofactor, reducing it to NADH. Heavy chronic alcohol use therefore shifts the hepatic and systemic NAD+/NADH redox balance toward an elevated NADH state, altering the metabolic environment of multiple organ systems^[7]. The hypothesis that restoring NAD+ could help reverse this redox imbalance and support recovery is biochemically coherent, even if it has never been tested in a clinical trial.

Second, the broader neurobiological pathway. NAD+ is a co-substrate for sirtuins (SIRT1–7) and PARPs, enzyme families implicated in gene regulation, stress response, and neuronal survival^[1][2]. Chronic substance use — across opioids, alcohol, and stimulants — disrupts dopaminergic reward circuitry in the nucleus accumbens and prefrontal cortex. Sirtuins have been proposed to influence this circuitry^[3]. The theoretical chain: IV NAD+ → raised intracellular NAD+ → activated sirtuin signaling → restored dopamine homeostasis → reduced craving. This chain is plausible at each individual link in animal models, but it has not been demonstrated causally in a controlled human trial of IV NAD+ infusion for addiction^[3].

Braidy and colleagues (2020), in a dedicated review of NAD+ and addiction published in Antioxidants, concluded that while "components of NAD+ metabolism and NAD-dependent enzymes can influence major signalling processes associated with the neurobiology of addiction," clinical studies of NAD+ for addiction treatment are "limited"^[3]. A review explicitly acknowledging limited clinical evidence is itself an important signal about the state of the field.

The actual published evidence — case series and observational data only

A PubMed search for randomized controlled trials of intravenous NAD+ infusion for addiction, substance use disorder, craving reduction, or withdrawal returns zero results as of July 2026. The evidence base that does exist consists of mechanistic reviews, animal studies, and a single published clinical series.

The most cited clinical publication is Blum and colleagues (2022), published in Current Psychiatry Research and Reviews^[4]. The study enrolled 50 adults with substance use disorder resistant to standard treatment and administered IV NAD+ combined with an enkephalinase inhibitor. Outcomes were self-reported Likert-scale scores for craving, anxiety, and depression, compared from baseline to post-treatment. The authors found statistically significant reductions in all three measures and reported that urine screens on a subset of 40 patients mid-study showed no illicit substance use.

What this study is not: randomized, blinded, or controlled. There was no placebo arm — meaning any observed improvement is indistinguishable from placebo response, the general therapeutic benefit of intensive clinical attention, or spontaneous improvement. Craving, anxiety, and depression are among the outcomes most susceptible to expectation effects. The lead author (KB) is the inventor of the enkephalinase-inhibition component and holds patents on the formulation — a substantial conflict of interest declared in the paper itself. The authors explicitly acknowledge that "larger randomized double-blinded placebo-controlled studies are needed" to validate their findings. The paper is best understood as preliminary pilot data generating a hypothesis that has not yet been tested rigorously, not as evidence of efficacy^[4].

No other peer-reviewed clinical trial — controlled or uncontrolled — of IV NAD+ for addiction recovery appears in PubMed as of July 2026. Anecdotal clinic reports and testimonials from wellness providers are not the same as published, peer-reviewed evidence. The field of NAD+ and addiction is genuinely interesting and mechanistically plausible^[3]; the controlled clinical evidence needed to support IV NAD+ as a treatment does not yet exist.

Evidence summary: claims vs. reality

What the evidence-based alternatives actually show

The contrast with evidence-based addiction treatments is stark. For opioid use disorder (OUD), medications for opioid use disorder (MOUD) have the strongest evidence base in addiction medicine. Mattick and colleagues' Cochrane review of buprenorphine versus placebo or methadone (2014) — covering multiple randomized controlled trials — found buprenorphine significantly superior to placebo for retaining patients in treatment and suppressing illicit opioid use^[6]. Naltrexone (extended-release injectable) is similarly supported by controlled trial data. These medications work by directly modulating opioid receptor activity, with measurable, replicable outcomes in blinded trials.

For alcohol use disorder (AUD), McPheeters and colleagues' 2023 JAMA systematic review and meta-analysis — covering 118 RCTs — found naltrexone (oral and extended-release injectable) and acamprosate significantly reduced alcohol consumption and relapse versus placebo^[5]. These medications have been tested in thousands of patients across multiple independent trials, with blinded outcome assessment and rigorous follow-up. They are FDA-approved for AUD, integrated into clinical guidelines, and covered by most insurance plans.

IV NAD+ has none of this. A single uncontrolled pilot with 50 patients, no placebo arm, and a conflict-of-interest-declared lead author^[4] is not comparable to the evidence base supporting MOUD or FDA-approved AUD pharmacotherapy. This is not a critique of NAD+ biology — it is a statement about the current state of clinical evidence. A treatment can be mechanistically interesting and clinically unproven at the same time.

Why this matters for a vulnerable population

Addiction is a high-stakes medical condition. Opioid use disorder is associated with a 20-fold increase in premature mortality, primarily from overdose. People seeking treatment are often in acute distress, financially strained, and willing to try anything that might work. This makes the addiction-recovery space particularly susceptible to unproven therapies — and the consequences of substituting an unproven treatment for evidence-based care can be severe: treatment delay, relapse, or overdose during the window when MOUD could have prevented it.

Multi-day IV NAD+ "detox protocols" that cost $1,000–$5,000+ are marketed specifically to people who may be seeking an alternative to standard treatment — sometimes explicitly positioned as a replacement for MOUD, not a complement to it. A clinic that promotes IV NAD+ as the primary or preferred treatment for opioid or alcohol dependence, without clearly communicating the absence of RCT evidence and the strength of evidence for MOUD, is doing a disservice to a population that deserves accurate information.

IV NAD+ infusion is not inherently harmful in the sense of causing known serious adverse effects at standard doses — the main documented risks are infusion-site discomfort, transient nausea, and flushing during administration. The harm is primarily one of substitution: time, money, and opportunity cost spent on an unproven treatment instead of, or while delaying, evidence-based care. For a condition as serious as OUD or severe AUD, that substitution risk is not trivial.

This article is educational and does not constitute medical advice. Every citation is sourced to peer-reviewed literature indexed in PubMed, verified against the live PubMed database on 2026-07-07. The statement that IV NAD+ has zero published RCTs for addiction reflects a July 2026 PubMed search for controlled human trials of intravenous NAD+ infusion for substance use disorder, addiction, withdrawal, or craving — returning zero results. Limitations of the Blum 2022 study (PMID 36118157) are reported directly from the paper's own methods and conflict-of-interest disclosure. Cost ranges for IV NAD+ "detox protocols" reflect market pricing observed across wellness clinic websites; actual prices vary. SAMHSA National Helpline: 1-800-662-4357 (24/7, free, confidential). Discuss addiction treatment options with a licensed addiction medicine specialist or your primary care provider.